Krebs Biochemicals And Industries Profile
Key Indicators
- Authorised Capital ₹ 153.00 Cr
- Paid Up Capital ₹ 151.56 Cr
- Company Age 33 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 14.35 Cr
- Satisfied Charges ₹ 285.88 Cr
- Revenue Growth -13.32%
- Profit Growth 44.55%
- Ebitda 53.58%
- Net Worth -32.45%
- Total Assets -7.81%
About Krebs Biochemicals And Industries
Krebs Biochemicals And Industries Limited (KBAIL) is a leading Public Limited Indian Non-Government Company incorporated in India on 02 December 1991 and has a history of 33 years and two months. Its registered office is in Visakhapatnam, Andhra Pradesh, India.
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 524518 and on the National Stock Exchange(NSE) under KREBSBIO.
The Corporate was formerly known as Krebs Biochemicals Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 153.00 Cr and a paid-up capital of Rs 151.56 Cr.
The company currently has active open charges totaling ₹14.35 Cr. The company has closed loans amounting to ₹285.88 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Krebs Biochemicals And Industries Limited India are Jitendra Shah as Ceo, Rakesh Kalbate as Company Secretary, and Ritesh Jain as Cfo. Venkata Gundapaneni, Ravi Tagore, Avinash Ravi, and Five other members serve as directors at the Company.
Company Details
- Location
Visakhapatnam, Andhra Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
Industry
What products or services does Krebs Biochemicals And Industries Limited offer?
Krebs Biochemicals And Industries Limited offers a wide range of products and services, including Bio Chemicals, Adenine Chemical.
Who are the key members and board of directors at Krebs Biochemicals And Industries?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jitendra Shah  | Managing Director | 09-Nov-2021 | Current |
| Rakesh Kalbate | Company Secretary | 14-Jun-2024 | Current |
| Ritesh Jain | CFO | 03-Feb-2023 | Current |
Board Members (7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Malati Tangirala | Director | 13-Feb-2015 | Current |
| Venkata Gundapaneni | Director | 13-Aug-2014 | Current |
| Ravi Tagore | Director | 12-Oct-1992 | Current |
| Avinash Ravi | Director | 01-Feb-2009 | Current |
| Raj Verma | Director | 12-Feb-2016 | Current |
| Pabitrakumar Bhattacharyya | Director | 30-Jul-2021 | Current |
Financial Performance of Krebs Biochemicals And Industries.
Krebs Biochemicals And Industries Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 13.32% decrease. The company also saw a substantial improvement in profitability, with a 44.55% increase in profit. The company's net worth observed a substantial decline by a decrease of 32.45%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Krebs Biochemicals And Industries?
In 2023, Krebs Biochemicals And Industries had a promoter holding of 72.74% and a public holding of 27.25%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Visakha Foods Private LimitedAvinash Ravi is a mutual person
_PRIVATE_LIMITED.webp)
Pre Unique (India) Private LimitedVenkata Gundapaneni is a mutual person
Numantra Technologies Private LimitedRaj Verma is a mutual person
Resonance Specialties LimitedRaj Verma is a mutual person
Makers Laboratories LtdRaj Verma is a mutual person
Mahaveer Infoway LimitedSatish Khivsara is a mutual person
Charges (Loans)
₹14.35 Cr
₹285.88 Cr
Charges Breakdown by Lending Institutions
- Others : 10.00 Cr
- Industrial Development Bank Of India : 3.00 Cr
- State Bank Of India : 1.35 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 26 Aug 2021 | Others | ₹10.00 Cr | Open |
| 16 Apr 1994 | State Bank Of India | ₹1.35 Cr | Open |
| 19 Jan 1986 | Industrial Development Bank Of India | ₹3.00 Cr | Open |
| 25 Aug 2020 | Others | ₹10.00 Cr | Satisfied |
| 08 Sep 2011 | Pinky Ventures Private Limited | ₹2.00 Cr | Satisfied |
How Many Employees Work at Krebs Biochemicals And Industries?
Krebs Biochemicals And Industries has a workforce of 335 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Krebs Biochemicals And Industries, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Krebs Biochemicals And Industries's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
